Prescient Therapeutics – Interview with Dr Allen Ebens
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a
Australian listed biotechnology company Prescient Therapeutics (ASX: PTX) today updated the market on progress on one of its